You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,389,480


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,389,480
Title:G protein coupled receptor agonists and antagonists and methods of activating and inhibiting G protein coupled receptors using the same
Abstract: The invention relates generally to G protein coupled receptors and in particular to agonists and antagonists of G protein receptors and methods of using the same.
Inventor(s): Kuliopulos; Athan (Winchester, MA), Covic; Lidija (Somerville, MA)
Assignee: Tufts Medical Center, Inc. (Boston, MA)
Application Number:12/558,276
Patent Claims:1. A polypeptide comprising: a) a first domain comprising an intracellular loop, or a fragment thereof, of a G protein coupled receptor (GPCR), wherein said GPCR is a Class A or Class B GPCR, and wherein said fragment comprises at least 3 contiguous amino acid residues of the intracellular loop, and b) a second domain, attached to the first domain, wherein said second domain comprises a cell-penetrating, membrane-tethering hydrophobic moiety comprising: a tridecanoyl (C.sub.13), myristoyl (C.sub.14), pentadecanoyl (C.sub.15), palmitoyl (C.sub.16), phytanoyl (methyl substituted C.sub.16), heptadecanoyl (C.sub.17), stearoyl (C.sub.18), nonadecanoyl (C.sub.19), arachidoyl (C.sub.20), heniecosanoyl (C.sub.21), behenoyl (C.sub.22), trucisanoyl (C.sub.23), a lignoceroyl (C.sub.24), a cholesterol, a phospholipid, a steroid, a sphingosine, a ceramide, an octyl-glycine, a 2-cyclohexylalanine, or a benzolylphenylalanine, wherein said polypeptide does not comprise an extracellular portion of the GPCR; and wherein said polypeptide is an agonist or antagonist of said GPCR.

2. The polypeptide of claim 1, wherein said first domain comprises at least 5 contiguous amino acid residues of the intracellular loop.

3. The polypeptide of claim 1, wherein said first domain comprises at least 7 contiguous amino acid residues of the intracellular loop.

4. The polypeptide of claim 1, wherein the first domain comprises 7 to 24 contiguous amino acid residues of the intracellular loop.

5. The polypeptide of claim 1, wherein the second domain comprises a steroid.

6. The polypeptide of claim 1, wherein the second domain comprises a moiety that is selected from the group consisting of a cholesterol, a phospholipid, a steroid, a sphingosine, a ceramide, an octyl-glycine, a 2-cyclohexylalanine, and a benzolylphenylalanine.

7. The polypeptide of claim 1, wherein the second domain comprises a moiety that is selected from the group consisting of a tridecanoyl (C.sub.13), myristoyl (C.sub.14), pentadecanoyl (C.sub.15), palmitoyl (C.sub.16), phytanoyl (methyl substituted C.sub.16), heptadecanoyl (C.sub.17), stearoyl (C.sub.18), nonadecanoyl (C.sub.19), arachidoyl (C.sub.20), heniecosanoyl (C.sub.21), behenoyl (C.sub.22), trucisanoyl (C.sub.23), and a lignoceroyl (C.sub.24) moiety.

8. The polypeptide of claim 7, wherein the second domain comprises a moiety that is a palmitoyl (C.sub.16), pentadecanoyl (C.sub.15) or myristoyl (C.sub.14) moiety.

9. The polypeptide of claim 1, wherein the G-protein coupled receptor is selected from the group consisting of a luteinizing hormone receptor, a follicle stimulating hormone receptor, a thyroid stimulating hormone receptor, a calcitonin receptor, a glucagon receptor, a glucagon-like peptide 1 receptor (GLP-1), a metabotropic glutamate receptor, a secretin receptor, a growth hormone releasing factor (GRF) receptor, a protease-activated receptor (PAR), a cholecystokinin receptor, a somatostatin receptor, a melanocortin receptor, an ADP receptor, an adenosine receptor, a thromboxane receptor, a platelet activating factor receptor, an adrenergic receptor, a 5-HT receptor, CXCR4, CCR5, a chemokine receptor, a neuropeptide receptor, an opioid receptor, a parathyroid hormone (PTH) receptor, a vasoactive intestinal peptide (VIP) receptor, a C5a anaphylatoxin receptor, an Fmet-leu-phe receptor, an APJ receptor, a Cannabis receptor, a lysosphingolipid receptor, an LPA (EDG) receptor, RDC1, and a gastric inhibitory peptide receptor.

10. The polypeptide of claim 1, wherein said G-protein coupled receptor is a mammalian G-protein coupled receptor.

11. The polypeptide of claim 10, wherein said G-protein coupled receptor is a protease-activated receptor (PAR).

12. The polypeptide of claim 11, wherein the protease-activated receptor is selected from the group consisting of PAR 1, PAR2, and PAR4.

13. The polypeptide of claim 1, wherein said G-protein coupled receptor is selected from the group consisting of Cholecystokinin A (CCKA) receptor, Cholecystokinin B (CCKB) receptor, Somatostatin Receptor Subtype 2 (SSTR2), and Substance P (SubP) receptor.

14. The polypeptide of claim 1, further comprising a third domain, said third domain being a cell-penetrating, membrane-tethering moiety attached to said first domain.

15. The polypeptide of claim 1, wherein the polypeptide further comprises 1-15 contiguous amino acid residues of a naturally-occurring transmembrane helix region of the GPCR immediately adjacent to the intracellular loop.

16. The polypeptide of claim 1, wherein said polypeptide further comprises 1-7 contiguous amino acid residues of a transmembrane helix region of the GPCR.

17. The polypeptide of claim 1, wherein the cell-penetrating, membrane-tethering hydrophobic moiety is attached to N-terminal amino acid residue of said first domain.

18. The polypeptide of claim 1, wherein said G protein coupled receptor is selected from the group consisting of an adrenergic receptor and an adenosine receptor.

19. The polypeptide of claim 1, wherein said G protein coupled receptor is an APJ receptor.

20. The polypeptide of claim 1, wherein said G protein coupled receptor is selected from the group consisting of a C5a anaphylatoxin receptor, a chemokine receptor, a lysosphingolipid receptor, an LPA (EDG) receptor, and an Fmet-leu-phe receptor.

21. The polypeptide of claim 20, wherein said chemokine receptor is selected from the group consisting of a CXCR4 receptor, a CCR5 receptor, and a RDC1 receptor.

22. The polypeptide of claim 1, wherein said G protein coupled receptor is selected from the group consisting of an ADP receptor, a thromboxane receptor, and a platelet activating factor receptor.

23. The polypeptide of claim 1, wherein said G protein coupled receptor is selected from the group consisting of a calcitonin receptor and a parathyroid hormone receptor.

24. The polypeptide of claim 1, wherein said G protein coupled receptor is selected from the group consisting of a glucagon receptor, a glucagon-like peptide 1 receptor (GLP-1), a gastric inhibitory peptide receptor, a vasoactive intestinal peptide receptor, a secretin receptor, a thyroid stimulating hormone receptor, a cholecystokinin receptor, and a growth hormone releasing factor receptor (GFR).

25. The polypeptide of claim 1, wherein said G protein coupled receptor is selected from the group consisting of a luteinizing hormone receptor and a follicle stimulating hormone receptor.

26. The polypeptide of claim 1, wherein said G protein coupled receptor is selected from the group consisting of a 5-HT receptor, a Cannabis receptor, a neuropeptide receptor, a somatostatin receptor, a melanocortin receptor and an opioid receptor.

27. The polypeptide of claim 1, wherein said G protein coupled receptor is a metabotropic glutamate receptor.

28. The polypeptide of claim 1, wherein said GPCR is a Class A GPCR.

29. The polypeptide of claim 1, wherein said GPCR is a Class B GPCR.

30. The polypeptide of claim 1, wherein the second domain comprises a palmitoyl (C.sub.16) moiety.

31. The polypeptide of claim 1, wherein the second domain comprises a pentadecanoyl (C.sub.15) moiety.

32. The polypeptide of claim 1, wherein the second domain comprises a myristoyl (C.sub.14) moiety.

33. The polypeptide of claim 1, wherein the second domain comprises a cholesterol.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.